NASDAQ · PTGX
Protagonist Therapeutics, Inc.
$136.11 +$0.68 (+0.50%) 1D After hoursKey Metrics
$8.71B
Market cap
—
P/E · TTM
—
Revenue · TTM
−$114.71M
Net income
EPS · TTM
$-1.82
Dividend yield
—
Free cash flow
−$117.90M
Beta · 1Y
0.14
EBITDA · TTM
−$113.93M
Gross margin
—
Snapshot
Market cap$8.71B
Enterprise value—
Shares outstanding64.3M
52-wk range$50.49 – $143.29
Avg volume · 20D893.6K
Net cash
—
Book value / share$10.41
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Protagonist Therapeutics, Inc.
IPO dateAug 11, 2016
Employees131
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases.
Wolf Grade COMING SOON
—
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.
Valuation
P/E—
P/S—
P/FCF—
EV/EBITDA—
EV/Sales—
Graham №—
Profitability
Gross
—
Operating
—
Net
—
FCF
—
ROE / ROIC
-17.2% · -106.5%
Financial Health
Current ratio17.76
Quick ratio—
Debt / equity—
Debt / EBITDA
—
Net cash
—
Working capital$578.91M
Cash Flow · TTM
Operating CF
−$116.64M
Capex
−$1.26M
Free cash flow
−$117.90M
Buybacks
—
Dividends paid
—
Shareholder yield
—
Piotroski F-Score
3 / 9
Weak fundamentals · 3 of 9 signals passing
Altman Z-Score
—
Insufficient balance-sheet inputs
Graham Number vs Price
—
Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings